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Background: Mammography screen-detected breast cancers have a better prognosis than predicted from established
prognostic markers. A search for additional features that are characteristic for these tumours and their prognosis is
needed to reduce overtreatment, a recognized challenge in breast cancer patient management today. Here, we have
investigated the occurrence and importance of tumour elastosis.
Methods: We performed a population based retrospective study of breast cancers detected in the Norwegian Breast
Cancer Screening Programme in Vestfold County during 2004–2009. In total, 197 invasive screen-detected cancers and
75 interval cancers in patients aged 50–69 years were compared with regard to standard clinico-pathological
parameters and tumour shape, as well as ER, PR, HER2 and Ki67 expression. In particular, the presence of elastotic
material in tumours was graded on a 4-tiered scale (score 0–3).
Results: Screen-detected cancers had a significantly higher content of stromal elastosis than interval cancers
(p < 0.001). High content of elastosis (score 3) correlated strongly with stellate tumour shape, low histological
grade, and ER+/HER2- status. Further, high elastosis score was significantly associated with lower Ki67 expression. In
survival analyses, cases with high elastosis demonstrated increased recurrence free (p = 0.03) and disease-specific
survival (p = 0.11) compared to cases with low elastosis.
Conclusion: There is a strong correlation between the presence of tumour elastosis, stellate tumour shape and
mammography detection of breast cancers. To our knowledge, this is the first time elastosis has been studied in
relation to breast cancer detection method. Presence of elastosis is associated with low tumour cell proliferation
(Ki67) and a good prognosis.
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The value of population-wide mammography screening
is controversial [1,2]. Thus, the introduction of mammog-
raphy screening for breast cancer has been associated with
up to 50% incidence increase in invited age groups [3-5].
Both tumour size and other prognostic factors are more
favourable for screened cancers than for symptomatic
(non-screened) tumours [6]. This is expected since the
aim of screening is to detect cancers early when cure is
possible. However, follow-up studies from different
countries indicate that screen-detected cancers have
more low-grade features and better outcome than pre-
dicted from tumour size, histological grade, and lymph
node status included in the Nottingham Prognostic Index
[7,8]. Furthermore, molecular subtyping of tumours can
only partly account for the difference [9-12]. There-
fore, a search for additional histological or molecular
characteristics of screen-detected cancers with an es-
pecially favourable prognosis is needed. Their identifi-
cation could result in less overtreatment, which is a
known challenge in breast cancer patient management
today [13].
Breast cancers are morphologically diverse and show a
wide spectrum of growth patterns and features such as
expression of ER, PR, HER2 and tumour cell prolifera-
tion. Recently, studies have also focused on the stroma
(microenvironment) surrounding tumour cells and provid-
ing growth conditions and support for malignant cells. The
tumour stroma consists of several components, including
extracellular matrix (composed of various proteoglycans
and fibrous proteins) [14], certain mesenchymal cells and
leukocytes, as well as the vasculature. Both histochemical
and molecular studies of breast cancer stroma have been
conducted [15-17], and one striking finding in many
tumours is the large aggregates of elastin fibres, known
as elastosis. This feature is also observed in radial
scars, a benign condition mimicking breast cancer on
mammograms [18].
Elastin is normally expressed in significant quantities
in skin, lung, cartilage, and large arteries, and it is pro-
duced by fibroblasts, smooth muscle cells and chondro-
cytes as a 72 kDa precursor tropoelastin, which is secreted
into the extracellular microenvironment. This protein is
cross-linked by lysyl oxidase (LOX) and complexes with
several smaller proteins, including fibrillin, to form large
structures with unique elastic properties [19]. In breast
cancer, elastin is observed as both individual fibres in the
stroma and large aggregates around ducts or small blood
vessels. The origin of the elastotic material has been
shown to be stromal cells like fibroblasts and myofibro-
blasts [20], but also the carcinoma cells [15,21]. Further, a
67 kD elastin receptor (EBP/S-gal) has been reported
[22,23], and receptor stimulation can affect cell prolifera-
tion, adhesion, and chemotaxis. In addition, elastin can becleaved into small peptide fragments, which can affect dif-
ferent cellular processes including apoptosis, chemotaxis,
and metastasis [23,24].
Elastosis was first studied in breast cancer decades ago
by Shivas & Douglas and others, showing that tumours
with large amounts of elastotic material had a better
prognosis [25,26]. Following this study, several groups
confirmed the correlation between elastosis and improved
breast cancer survival [27-29]. Further, there is a correl-
ation between elastosis and estrogen receptor expression
as well as response to anti-hormonal therapy [30,31]. On
this background, the aim of our study was to establish
whether there is a significant difference in elastosis
content between screen detected and interval breast
cancers, and whether elastosis is a marker of cancers
detected by mammography and a possible mediator of
their good prognosis. The study was based on material
from the population-based Norwegian Breast Cancer
Screening Programme.
Methods
Study population
Patients were included from Vestfold County in Eastern
Norway. Vestfold comprises 5% of the Norwegian popu-
lation with around 230,000 inhabitants. The Norwegian
Breast Cancer Screening Programme involves biannual
mammography in the age-group 50–69 years, and was
implemented in this county in 2004. The mean age of
the actual patients at the time of diagnosis was 60 years
(range 49–70 years). A total of 37,977 women partici-
pated during the study period March 2004 – June 2009
with attendance rates of 71% and 76%, respectively, during
the first two screening rounds. During this period, a total
of 285 patients with 202 invasive screen-detected cancers
and 83 invasive interval tumours were diagnosed during
the prevalent and subsequent rounds. The term interval
cancer refers to a breast cancer diagnosed between two
screening sessions. Ten patients (3 screening and 7 inter-
val) were excluded because only core biopsies were avail-
able from these locally advanced tumours; the evaluation
of elastosis content was limited to cases where standard
sections were available (cases treated by primary surgery).
In addition, 3 other patients were excluded: 1 screen-
detected cancer had no residual tumour tissue for further
investigation; 1 screen-detected case was diagnosed as a
malignant phyllodes tumour, and 1 patient with interval
cancer suffered from multiple metastases at the time of
diagnosis, and no biopsy or surgery of the breast was per-
formed. Four patients (two screening-patients and two
interval-patients) had simultaneous tumours in both
breasts. To represent the case for this particular study, the
Nottingham Prognostic Index (NPI) was used for three of
them, to select the tumour with charateristics of the worst
prognosis. The fourth patient had an identical NPI in both
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sequently selected for our study. Thus, a total of 272
patients with 197 from the screening group and 75
from the interval group were included for this
population-based study. Clinical data (stage and sur-
vival) were recorded from patient journals (last clinical
status June 2013). The study was approved by the Re-
gional Ethics Committee of Eastern Norway (registration
number S-08685d).
Histopathological data
All cases were re-examined by microscopy by one of the
authors (T.A.K.) by using standard HES stained sections.
Tumours were classified as either ductal, lobular or
other types of carcinomas. Histological grading was done
according to the Nottingham criteria [32]. Tumour diam-
eter was measured microscopically in mm, and lymph
node status was included from the pathology report. For
this study, all tumours underwent standard immunohisto-
chemical staining for ER, PR and HER2. For ER and PR,
positivity was defined as staining in ≥ 10% of the tumour
cell nuclei. In equivocal HER2 cases (2+ according to
the HerCep test criteria), in situ hybridization by FISH
analysis was done. Amplification was defined as a
HER2/Chromosome 17 ratio of ≥ 2 [33].BA
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Figure 1 Histological and radiological images of screen-detected and
whole tumour images of a screen-detected cancer with stellate shape and
in C). Middle row: Comparable images of an interval cancer with rounded,
Magnification x 5. Lower row: Higher magnification (x200) of histological sl
H, elastin-staining.Ki67
Tissue microarray slides from the tumour set were used
for Ki67 evaluation. The slides were dewaxed with xylene/
ethanol before microwave antigen retrieval for 20 min in
TRS buffer (pH9). The slides were incubated for 30 min
with a monoclonal Ki67 antibody (M7240, clone MIB-1)
(Dako), diluted 1:100. The staining was performed using
the EnVision-labelled polymer method. 500 tumour cell
nuclei were counted, and the Ki67 positive fraction was
calculated.
Further histological evaluation was done in conjunc-
tion by two authors (Y.C. and J.L.) in a blinded manner
for the following parameters:
Tumour elastosis
The amount of elastotic stroma in the tumour, which
was evaluated in cases with standard sections available,
was graded by microscopy in a semiquantitive manner
from 0 – 3, according to Shivas & Douglas [25]. This
method refers to elastin-stained microscopic slides, but
elastosis can also easily be recognized in standard HES
slides as a deposit of grey, fibrillary material. In grade 0,
elastosis was absent; in grade 1, small deposits (single
elastin fibrils or a thin rim of elastosis around ducts)
were present; in grade 2, thicker zones of elastosis wereC
F
H
interval breast cancer. Upper row: Radiological (A) and histological
abundant stromal elastosis (grade 3) (HES staining in B; elastin-staining
pushing-border contour and no stromal elastosis (grade 0) (D-F).
ides from the screening cancer in the upper row. G, HES-staining.
Table 1 Methods of elastin fiber visualization: HES
staining versus elastin special stain*
Elastosis grade using HES stain
Elastin stain 0 1 2 3 Total
0 56 1 0 0 57
1 35 54 2 0 91
2 1 23 51 0 75
3 0 0 4 45 49
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areas of the tumour. Both evaluation methods for elastin
were used in the present study. Elastosis was graded
without knowledge of other features or method of detec-
tion. In some of the statistical analyses, elastosis was di-
vided into two categories, low (grade 0 to 2) and high
(grade 3). Morphologically, this cut-off point corresponds
to cases with no or limited elastosis (grade 0–2) compared
to cases with extensive elastosis (grade 3).Total 92 78 57 45 272
Elastosis was graded semiquantitatively from 0–3 using either stain.
*p-value < 0.001 for comparison (Kendall´s test).Tumour shape
The contour shape of the tumour was evaluated in
whole tumour slides. If tumour processes (containing
tumour cells) were radiating into surrounding tissue,
the tumour shape was classified as stellate [34,35]. Tu-
mours that lacked these features were classified as round.
These tumours typically had pushing border growth.Table 2 Breast cancer detection method in association
with clinical and histopathological characteristics
Detection method
Marker Screening Interval
n (%)* n (%)* p-value**
Age 60.0 (5.7) 60.0 (5.7) NSNecrosis
Presence of necrotic areas in the infiltrating tumour
tissue (not necrosis in DCIS areas) was noted. A necrotic
focus was defined as a confluent area of necrosis detect-
able at intermediate magnification (x40), containing at
least 10–15 necrotic cells [36].Tumour diameter 14.0 (9.9) 16.0 (13.1) NS
Histological type NS
Ductal 159 (81) 61 (81)
Lobular 23 (12) 10 (14)
Other 15 (7) 4 (5)
Histological grade <0.001Fibrotic focus
The presence of a large collagenous area devoid of carcin-
oma cells, usually in the center of the tumour, was noted.
This has previously been linked to worse prognosis in
breast cancer [37,38]. A fibrotic focus does not contain
elastosis.Grade 1 63 (32) 12 (16)
Grade 2 107 (54) 32 (43)
Grade 3 27 (14) 31 (41)
Nodal status NS
N0 136 (69) 45 (60)
N1+ 61 (31) 30 (40)
ER 0.001
Positive 180 (91) 57 (76)
Negative 17 (9) 18 (24)
PR NS
Positive 133 (67) 48 (64)
Negative 64 (33) 27 (36)
HER2 NS
Negative 184 (93) 65 (87)
Positive 13 (7) 10 (13)
Ki67 (median) 10 (12,9) 12,0 (17,5) NS
*Number of cases (n and %) is given except for age, tumour diameter and
Ki67, where median and standard deviation (SD) is given.
**Pearson's Chi-square test except for age, tumour diameter and Ki67 where
Mann–Whitney U test was applied.Statistical analysis
All statistical analyses were performed with IBM SPSS
Statistics, version 21.0 (Armonk, NY: IBM Corp.).
Two-sided p-values of <0.05 were considered statisti-
cally significant. Associations between different cat-
egorical variables were assessed by Pearsons χ2 test or
Kendall´s test. Mann–Whitney U test was used for
analysis of age, tumour diameter and Ki67 between cat-
egories. Univariate survival analyses of time to death
due to breast cancer (disease specific survival) and
time to recurrence for patients without metastases at
the time of diagnosis (recurrence free survival), were
performed using the Kaplan–Meier method (log-rank
test). Entry date was the time of diagnosis. Patients
who died from other causes were censored at the date
of death in the analyses of disease specific survival. For
statistical analyses, tumour elastosis was dichotomized;
high elastosis (grade 3) and low elastosis (grade 0–2).
A total of 272 patients were accessible for survival analysis
in the current study.Results
Elastosis content
Figure 1 shows tumours with typical elastosis grade 3
and 0, respectively. Table 1 shows a comparison of elas-
tin content by HES sections and elastin special stain in
all samples. Although significantly correlated (p < 0,001),
Table 4 Correlation between elastosis (high/low) and
clinico-pathological features
Elastosis (HES slides)
Marker Low elastosis (0–2) High elastosis (3)
n (%)* n (%)* p-value**
Age 60.0 (5.7) 63.0 (5.2) NS
Tumour diameter 15,0 (11.3) 14,0 (8.7) NS
Histological type NS
Ductal 184 (81) 36 (80)
Lobular 26 (12) 7 (16)
Other 17 (7) 2 (4)
Histological grade <0.001
Grade 1 53 (23) 22 (49)
Grade 2 117 (52) 22 (49)
Grade 3 57 (25) 1 (2)
Nodal status NS
N0 147 (65) 34 (76)
N1+ 80 (35) 11 (24)
ER 0.005
Positive 192 (85) 45 (100)
Negative 35 (15) 0 (0)
PR 0.04
Positive 145 (64) 36 (80)
Negative 82 (36) 9 (20)
HER2 0.03
Chen et al. Diagnostic Pathology  (2014) 9:230 Page 5 of 8some discordant cases were observed. Elastin staining
colours the fibres black which explains a higher sensitivity
than visual recognition of the grey material in HES-slides.
Thus, a proportion of HES negative slides were 1+ by elas-
tin staining, and likewise for HES 1+ being 2+ with elastin
stain. There was almost complete concordance between
HES 3+ and elastin-stain 3+ cases.
Characteristics of tumours detected by screening versus
interval cancers
Table 2 presents the basic clinico-pathological features
and Table 3 the special histopathological evaluation of
breast carcinomas in relation to detection method in the
study population. As expected, histological grade was
significantly higher in interval cancers; the proportion of
grade 3 tumours was 14% in the screen-detected group
and 40% in the interval cancer group. Tumour size and
frequency of lymph node involvement were moderately
higher for the interval versus screen-detected cancers.
ER positivity was more frequent in screen-detected cancers,
whereas PR and HER2 expression were not significantly
different in this study.
Further, screen-detected cancers were significantly
associated with star-shape (Figure 1) and absence of ne-
crosis (Table 3). Also, high elastosis content was more
frequent in the screen-detected cancers; 44% of these tu-
mours were 2+ or 3+ compared with 19% among inter-
val cancers; 52% of interval tumours lacked elastosis
altogether, compared with only 27% of screen-detectedTable 3 Breast cancer detection method in association
with tumour shape and stromal characteristics
Detection method
Marker Screening Interval p-value**
n (%)* n (%)*
Tumour shape 0.001
Star 143 (73) 37 (51)
Round 54 (27) 36 (49)
Elastosis# <0.001
0 53 (27) 39 (52)
1 56 (29) 22 (29)
2 46 (23) 11 (15)
3 42 (21) 3 (4)
Fibrotic focus NS
No 178 (90) 64 (87)
Yes 19 (10) 10 (13)
Necrosis 0.012
No 183 (93) 62 (83)
Yes 14 (7) 13 (17)
*Number of cases (n and %).
**Pearson`s chi-square test.
#Graded on HES-slides.
Negative 204 (90) 45 (100)
Positive 23 (10) 0 (0)
Ki67 12,0 (15,2) 7,0 (6,6) <0.001
Tumour shape <0.001
Star 136 (60) 44 (98)
Round 89 (40) 1 (2)
Fibrotic focus 0.011
No 197 (87) 45 (100)
Yes 29 (13) 0 (0)
Necrosis 0.015
No 200 (88) 45 (100)
Yes 27 (12) 0 (0)
*Number of cases (n and %) is given except for age, tumour diameter and
Ki67, where median and standard deviation (SD) is given.
**Pearson's chi-square test except for age, tumour diameter and Ki67 where
Mann–Whitney U test was applied.cancers. Presence of a fibrotic focus was not significantly
different in the two groups.
High elastosis content associates with clinico-pathological
characteristics of good prognosis
High stromal elastosis was associated with ER and PR
expression and HER2 negativity (Table 4). Also, tumours
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with stellate tumour shape and absence of fibrosis and
necrosis (Table 4). There was significantly more frequent
low-grade tumours in the high-elastosis cases, compared
to tumours with low elastosis. High elastosis score was
also significantly associated with lower tumour cell pro-
liferation by Ki67 expression (Figure 2 and Table 4).
Tumour size, histological type, lymph node status, and
distant metastasis did not show a significant correlation
with elastosis.
Survival analysis
The median follow-up period was 71 months (range 2–
117 months). Among 272 patients finally included, distant
metastases or local tumour recurrence were observed at
follow-up in 31 (12 %), and 22 patients (8 %) died of breast
cancer.
In univariate survival analyses, high elastosis content
was significantly associated with longer recurrence-free
survival as compared to cases with low elastosis (5-year
survival 98% and 90 %, respectively, Figure 3A). High
elastosis was also associated with longer disease specific
survival, although of borderline significance (98% and
96%, respectively, Figure 3B).
Discussion
Breast cancers detected by mammography screening
have a particularly good prognosis, better than predicted
by standard clinico-pathological features. A tumour
stroma rich in elastin fibre aggregates (elastosis) is a
frequent finding in breast cancer. By comparing screen-
detected and interval cancers in a population-based ma-
terial from the Norwegian Breast Cancer Screening
Programme, we here found a strong correlation betweenHigh elastosisLow elastosis
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Figure 2 High elastosis is significantly associated with low
proportion of Ki67 positive tumour cells. The relationship
between high/low elastosis and % Ki67 positive tumour cells are
demonstrated in the dot-blot.
Figure 3 Elastosis is associated with survival in breast cancer.
Low elastosis (evaluated by HES-section) associates with reduced
recurrence-free (A) and disease specific (B) survival. For each category,
the number of cases is given followed by the number of breast cancer
recurrences or deaths.screening detection and tumour elastosis. High content
of elastosis in turn showed strong covariation with other
predictors of good prognosis such as low histological grade,
hormone receptor expression, HER2 negative tumours, and
low tumour cell proliferation by the Ki67 index. Also, sig-
nificantly improved recurrence free survival was observed
in tumours with high elastin content. To our knowledge,
this is the first time elastosis content is studied in relation
to breast cancer detection method.
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which is frequent in lesions detected by mammography.
Mammographic spiculation has previously been found
to correlate with good prognostic factors [39,40]. More-
over, one study showed that mammographic spiculation
was an independent prognostic factor for screen-detected
breast cancer [39]. In another study, not stratified by de-
tection method, small breast cancers (less than 15 mm)
with stellate mammographic pattern had a better survival
[41]. A previous study found that stellate ductal carcin-
omas (termed “scar cancer”) were related to markers of
good prognosis such as small tumour size and hormone
receptor positivity [34]. Since mammography detection of
malignancy is partly based on the recognition of a stellate
tumour pattern, this detection method appears to be
biased towards low-grade and good-prognosis tumours.
Because of its association with stellate morphology,
tumour elastosis may be one factor that mediates this
favourable prognosis.
In contrast to screen-detected breast cancer in our
study, interval cancers typically had low or absent elasto-
sis content. They tended to have a rounded shape, and
displayed necrosis more frequently, the latter reflecting
their more aggressive phenotype. These tumours also
had higher histological grade and Ki67 index and were
more often hormone receptor negative and HER2 posi-
tive, which is in accordance with previous studies [12].
What is the biological significance of aggregation of
large quantities of elastin fibres in breast cancer stroma?
Is there a mechanistic link between the presence of elastin
and a better prognosis? The angiostatic molecule endosta-
tin has been reported to accumulate on elastin fibres [42],
and this could reduce angiogenesis and hence tumour
growth and spread. In contrast, effects could be related
to elastin itself, the elastin receptor, or elastin derived
peptides. Some elastin-related effects may be mediated
by elafin, an inhibitor of elastase, which recently has
been shown to be a positive prognostic factor in breast
cancer [43]. Other recent studies have addressed the
mechanical properties of tumour tissue, establishing a
correlation with aggressive behavior in collagen-rich
tumours [44]. Hypothetically, a high content of elastin
may affect the mechanical properties and prognosis in
the opposite direction. The elucidation of these mecha-
nisms needs further investigation.
Mammography screening has been criticized for only a
small reduction in breast cancer mortality, although
studies differ in their estimates [45-47]. At the same
time, screening significantly increases the incidence of
invasive breast cancer, in some studies by up to 50% in
the invited age group. This has lead to the hypothesis
that a subgroup of screen-detected tumours would never
manifest clinically because they remain dormant or
regress spontaneously [3]. It is tempting to speculatethat large areas of elastosis could be relevant in this con-
text. At least, elastosis is probably not a favourable
microenvironment for tumour growth and spread.
Conclusions
Our results indicate a strong correlation between the
presence of tumour elastosis and mammography detection
of breast cancers, and there was also an association with
stellate tumour shape, a frequent detection criterion by
mammography. The presence of elastosis was associated
with low-grade tumours and good prognosis. Whether and
how elastosis is mechanistically involved in tumour develop-
ment and progress requires further study.
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